Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100197Source: DataRank Database

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC is a research paper published in JTO Clinical and Research Reports (2021). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)OA: goldTopics (10)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Michael Offin ORCID,Annemarie F. Shepherd ORCID,Matthew D. Hellmann ORCID,Daniel R. Gomez ORCID,Jamie E. Chaft ORCID

Live enrichment

PubMed:34590042 PMC:PMC8474390

National Cancer Institute

Grant: P30 CA008748

AstraZeneca

Grant: PCT/US2015/062208

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

Merck Sharp and Dohme

National Institutes of Health

Novartis

Pfizer

Bristol-Myers Squibb

Boehringer Ingelheim

Merck

American Society of Clinical Oncology

Varian Medical Systems

goldLicense: cc-by-nc-nd

publisherhttps://doi.org/10.1016/j.jtocrr.2021.100197

publisherhttps://api.elsevier.com/content/article/PII:S2666364321000564?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364321000564?httpAccept=text/plain

repositoryhttp://europepmc.org/pmc/articles/PMC8474390

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8474390

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

ToxicityPneumonitisChemoradiationStage Iii NsclcDurvalumabBrief ReportNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282

Sustainable Development Goals

SDG 3: 3. Good health

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

FAIR Checklist

Authors (7)

Funding (12 grants)

Open Access

Topics

Annotations (Europe PMC)